Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (218)
  2. Journal Article (126)
  3. Review (18)
  4. Research Letter (7)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (2)
  8. Editorial (2)
Groups
  1. Adult Leukemia (378)
  2. Center for Hematologic Malignancies (378)
  3. Department of Medicine (378)
  4. Hematologic Malignancies, Division of (378)
  5. GSK Faculty (188)
  6. Hematologic Malignancies Research (145)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (85)
  3. Maria Palomba (84)
  4. Michel Sadelain (84)
  5. Martin Tallman (81)
  6. Miguel-Angel Perales (72)

More People

Years
  1. 2025 (26)
  2. 2024 (38)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (147)
  2. Journal of Clinical Oncology (31)
  3. Blood Advances (14)
  4. Haematologica (9)
  5. Leukemia and Lymphoma (9)
  6. Transplantation and Cellular Therapy (9)

More Publications

Publishers
  1. American Society of Hematology (161)
  2. Elsevier Inc. (35)
  3. American Society of Clinical Oncology (33)
  4. Nature Publishing Group (30)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (378)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NGS MRD negativity on day 28 after brexu cel in adults with R/R ALL is associated with favorable progression free survival
    Meeting Abstract

    Valtis, Y. K.; Nemirovsky, D.; Devlin, S. M.; Roloff, G. W.; Aldoss, I.; Jeyakumar, N.; Miller, K.; Zhang, A.; Sutherland, K. C.; Advani, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in the open-label, multi-center, global, single-arm, phase Ib/II FELIX study: The impact of bridging therapies on CAR T-cell expansion and persistence
    Meeting Abstract

    Park, J. H.; Jabbour, E.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; Deangelo, D. J.; Lao-Sirieix, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of immune reconstitution and their clinical significance in aggressive lymphoma treated with CAR-T therapy
    Meeting Abstract

    Luan, D. Y.; Dewolf, S.; Fei, T.; Raj, S. S.; Shah, G. L.; Lareau, C.; Alhomoud, M.; Salles, G.; Rivas-Delgado, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia
    Meeting Abstract

    Geyer, M. B.; Dewolf, S.; Mi, X.; Shaffer, B. C.; Cadzin, B.; McAvoy, D.; Hosszu, K. K.; Weis, K.; Lorenc, R.; Lewis, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Deep molecular remission may predict better outcomes
    Meeting Abstract

    Jabbour, E.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; DeAngelo, D. J.; Lao-Sirieix, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save